ArticleBlood2017
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 2 pooled it
18.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 2 syntheses or guidelines pooled it, 286 citations in OpenAlex.
- American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2026Guideline
- Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Pooled it
- Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.Blood neoplasia · 2026Trial
- Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.Blood advances · 2025Trial
- Randomized Phase III SIERRA Trial ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Trial
- Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia.American journal of hematology · 2020Trial
- GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party.Bone marrow transplantation · 2026Article
- Prognostic factors and a novel scoring system for allogeneic hematopoietic stem cell transplantation in patients aged 70 years or older: a nationwide registry analysis in Japan.Bone marrow transplantation · 2026Article
- Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes.Bone marrow transplantation · 2026Review
- Eligibility versus appropriateness in allogeneic HCT.Blood advances · 2026Article
- Impact of health insurance coverage on dentition status prior to hematopoietic cell transplant: A 10-year single-institution observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS.Blood advances · 2026Article
- Factors Associated with Receipt of Allogeneic Hematopoietic Cell Transplant and NMDP Donor Search in Older Adults with Acute Myeloid Leukemia.Transplantation and cellular therapy · 2026Article
- Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades.Blood advances · 2026Article
- Optimizing Patient Selection for Reduced Nonrelapse Mortality After Reduced-Intensity Conditioning: A CIBMTR Analysis.Transplantation and cellular therapy · 2026Article
- CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.Blood advances · 2026Article
- Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI).Bone marrow transplantation · 2026Article
- Outcomes of allogeneic hematopoietic cell transplantation in patients with carbapenem-resistant organisms infection: a propensity score-matched analysis.Frontiers in transplantation · 2026Article
- Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study.Blood cancer journal · 2025Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
51 authors at 20 institutions in 10 countries.
Lori MufflyDivision of Blood and Marrow Transplantation, Stanford University, Stanford, CA.
Marcelo C PasquiniCenter for International Blood and Marrow Transplant Research and.
Michael MartensDivision of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI.
Ruta BrazauskasCenter for International Blood and Marrow Transplant Research and.
Xiaochun ZhuCenter for International Blood and Marrow Transplant Research and.
Kehinde AdekolaNorthwestern Memorial Hospital, Chicago, IL.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia.
Karen K BallenDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, MA.
Ashish BajelRoyal Melbourne Hospital, Victoria, VIC, Australia.
Frederic BaronCentre Hospitalier Universitaire de Liege, Domaine Universitaire du Sart Tilman, Liege, Belgium.
Minoo BattiwallaHematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD.
Amer BeitinjanehDepartment of Hematology and Oncology, University of Miami, Miami, FL.
Jean-Yves CahnDepartment of Hematology, University Hospital, Grenoble, France.
Mathew CarabasiDepartment of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA.
Yi-Bin ChenDivision of Hematology/Oncology, Massachusetts General Hospital, Boston, MA.
Saurabh ChhabraDepartment of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.
Stefan CiureaDepartment of Stem Cell Transplantation and Cellular Therapy and.
Edward CopelanDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.
Anita D'SouzaCenter for International Blood and Marrow Transplant Research and.
John EdwardsIndiana Blood and Marrow Transplantation, Indianapolis, IN.
James ForanMayo Clinic, Jacksonville, FL.
Cesar O FreytesTexas Transplant Institute, San Antonio, TX.
Henry C FungDepartment of Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA.
Robert Peter GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
Sergio GiraltMemorial Sloan Kettering Cancer Center, New York, NY.
Shahrukh K HashmiDepartment of Internal Medicine, Mayo Clinic, Minneapolis, MN.
Gerhard C HildebrandtDepartment of Internal Medicine, University of Kentucky Chandler Medical Center, Lexington, KY.
Vincent HoCenter for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA.
Ann JakubowskiMemorial Sloan Kettering Cancer Center, New York, NY.
Hillard LazarusSeidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH.
Marlise R LuskinAbramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA.
Rodrigo MartinoDivison of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Richard MaziarzAdult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Philip McCarthyBlood and Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
Taiga NishihoriDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Rebecca OlinDepartment of Medicine, University of California San Francisco Medical Center, San Francisco, CA.
Richard F OlssonDivision of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Attaphol PawarodeBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI.
Edward PeresBone Marrow Transplant Program, Henry Ford Hospital, Detroit, MI.
Andrew R RezvaniDivision of Blood and Marrow Transplantation, Stanford University, Stanford, CA.
David RizzieriDivision of Hematologic Malignancies and Cellular Therapy, Blood and Marrow Transplant Clinic, Duke University, Durham, NC.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Harry C SchoutenDepartment of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands.
Mitchell SabloffDivision of Hematology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Matthew SeftelDepartment of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.
Sachiko SeoNational Cancer Research Center, East Hospital, Kashiwa, Chiba, Japan.
Mohamed L SorrorClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Jeff SzerDepartment Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Victoria, VIC, Australia.
Baldeep M WirkDivision of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA.
William A WoodDivision of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; and.
Andrew ArtzSection of Hematology/Oncology, University of Chicago School of Medicine, Chicago, IL.
Medical College of Wisconsin · USMassachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USStanford University · USThe Royal Melbourne Hospital · AUAlbert B. Chandler Hospital · USCancerCare Manitoba · CACentre Hospitalier Universitaire de Liège · BECHRISTUS Transplant Institute · USDana-Farber Cancer Institute · USDuke University · USFox Chase Cancer Center · USHenry Ford Hospital · USHospital de Sant Pau · ESImperial College London · GBIndiana Cancer Consortium · USKing Faisal Specialist Hospital & Research Centre · SALevine Cancer Institute · USMayo Clinic in Arizona · USMayo Clinic in Florida · US
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MNCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
Abstract
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HCT) in adults ≥70 years with hematologic malignancies across the United States. Adults ≥70 years with a hematologic malignancy undergoing first allogeneic HCT in the United States between 2000 and 2013 and reported to the Center for International Blood and Marrow Transplant Research were eligible. Transplant utilization and transplant outcomes, including overall survival (OS), progression-free survival (PFS), and transplant-related mortality (TRM) were studied. One thousand one hundred and six patients ≥70 years underwent HCT across 103 transplant centers. The number and proportion of allografts performed in this population rose markedly over the past decade, accounting for 0.1% of transplants in 2000 to 3.85% (N = 298) in 2013. Acute myeloid leukemia and myelodysplastic syndromes represented the most common disease indications. Two-year OS and PFS significantly improved over time (OS: 26% [95% confidence interval (CI), 21% to 33%] in 2000-2007 to 39% [95% CI, 35% to 42%] in 2008-2013,
Indexed as
AgedCohort StudiesDemographyFemaleHematopoietic Stem Cell TransplantationHumansMaleMultivariate AnalysisPrognosisTime FactorsTransplantation, HomologousTreatment OutcomeUnited States
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.